References
- Allison P. J., Locker D., Feine J. S. Quality of life: a dynamic construct. Social Science and Medicine 1997; 45: 221–230, [PUBMED], [INFOTRIEVE], [CSA]
- Ashton C. H. Benzodiazepine abuse. Drugs and Dependence. Harwood Academic Publishers, London and New York 2002; 197–212
- Barnett P. G., Rodgers J. H., Bloch D. A. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001a; 95: 683–690, [CROSSREF], [CSA]
- Barnett P. G., Zaric G. S., Brandeau M. L. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 2001b; 96: 1267–1278, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Belding M. A., Iguchi M. Y., Morral A. R., Husband S. D. MMPI profiles of opiate addicts: predicting response to treatment. Journal of Personality Assessment 1986; 70: 324–339, [CSA]
- Belding M. A., McLellan A. T., Zanis D. A., Incmikoski R. Characterizing “non-responsive” methadone patients. Journal of Substance Abuse and Treatment 1998; 15: 485–492, [CROSSREF], [CSA]
- Bell J., Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug Safety 2000; 22: 179–190, [PUBMED], [INFOTRIEVE], [CSA]
- Bergner M. Quality of life, health status, and clinical research. Medical Care 1989; 27: 148–156, [CSA]
- Bertschy G. Methadone maintenance treatment: an update. European Archives of Psychiatry and Clinical Neuroscience 1995; 245: 114–124, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bickel W. K., Amass L. Buprenorphine treatment of opioid dependence: a review. Experimental and Clinical Psychopharmacology 1995; 146: 111–118, [CSA]
- Bigelow D. A., Gareau M. J., Young D. J. A quality of life interview for chronically disabled people. Psychosocial Rehabilitation Journal 1990; 14: 94–98, [CSA]
- Bigelow D. A., McFarland B. H., Olson M. Quality of life of community mental health program clients: validating a measure. Community Mental Health Journal 1991; 27: 43–55, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- BMGF—Bundesministerium für Gesundheit und Frauen. Suchtgiftbezogene Todesfälle. Bundesministerium für Gesundheit und Frauen, Vienna, Austria 2002
- Bradley B. P., Gossop M., Philips G., Legarda J. J. The Development of an Opiate Withdrawal Scale (OWS). British Journal of Addiction 1987; 82: 1139–1142, [PUBMED], [INFOTRIEVE], [CSA]
- Bridge T. P., Fudala P. J., Herbert S., Leiderman D. B. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug and Alcohol Dependence 2003; 70: 79–85, Suppl. 2[CROSSREF], [CSA]
- Bruera E., Fainsinger R. L. Pharmacologic treatment of cancer pain. New England Journal of Medicine 1997; 336: 962–963, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Caplehorn J. R. M., Ross M. W. Methadone maintenance and the likelihood of risky needle-sharing. International Journal of Addiction 1995; 30: 685–698, [CSA]
- Carrieri M. P., Rey D., Loundou A., Lepeu G., Sobel A., Obadia Y. Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users. Drug and Alcohol Dependence 2003; 72: 13–21, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Carroll K. M. Integrating psychotherapy and pharmacotherapy to improve drug abuse outcomes. Addictive Behaviors 1997; 22: 233–245, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cella D. F. Quality of life: concepts and definition. Journal of Pain and Symptom Management 1994; 9: 186–192, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chatham L. R., Hiller M. L., Rowan-Szal G. A., Joe G. W., Simpson D. D. Gender differences at admission and follow-up in a sample of methadone maintenance clients. Substance Use & Misuse 1999; 8: 1137–1165, [CSA]
- CIAD Group of Experts in Demand Reduction, Jamaica, August, 8–102001
- Craddock S. G., Rounds-Bryant J. L., Flynn P. M., Hubbard R. L. Characteristics and pretreatment behaviors of clients entering drug abuse treatment: 1969 to 1993. American Journal of Drug and Alcohol Abuse 1997; 23: 43–59, [PUBMED], [INFOTRIEVE], [CSA]
- Cumberbatch Z., Copersino M., Stitzer M., Jones H. Comparative drug use and psychosocial profiles of opioid dependents applying for medication versus medication-free treatment. American Journal of Drug and Alcohol Abuse 2004; 30: 237–249, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dazord A., Mino A., Page D., Broers B. Patients on methadone maintenance treatment in Geneva. European Psychiatry 1998; 13: 235–241, [CROSSREF], [CSA]
- Davids E., Gastpar M. Buprenorphine in the treatment of opioid dependence. European Neuropsychopharmacology 2004; 14: 209–216, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Derks J. T. M. The efficacy of the Amsterdam morphine-dispending programme. Drug Misuse and Dependence, H. A. Ghodse, C. D. Kaplan, R. D. Mann. Parthenon, Park Ridge, IL 1990; 85–108
- de Vos J., Ufkes J., van Brussel G., van den Brink W. Craving despite extremely high methadone dosage. Drug and Alcohol Dependence 1996; 40: 181–184, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Diener E. Subjective well being: three decades of progress. Psychological Bulletin 1999; 125: 276–302, [CROSSREF], [CSA]
- Dobler-Mikola A., Zimmer-Hofler D. Klientinnen drogentherapeutischer Gemeinschaften in der Schweiz zwischen 1978/79 und 1990/91. Drogalkohol. 1993; 2: 69–82, [CSA]
- Dole V. P., Nyswander M. E. A Medical Treatment for Diacetylmorphine (Heroin) addiction. Journal of American Medical Association 1965; 193: 80–84, [CSA]
- Dole V. P., Robinson J. W., Orraca J., Towns E., Searcy P., Caine E. Methadone treatment of randomly selected criminal addicts. New England Journal of Medicine 1969; 280: 1372–1375, [PUBMED], [INFOTRIEVE], [CSA]
- Donald A. What is quality of life?. Journal of Evidence-based Medicine 2001; 9: 1–6, [CSA]
- Eckstein G. Nachsorge: Netzwerk oder Stückwerk?. Suchtreport 1997; 1: 29–36, [CSA]
- Eder H., Fischer G., Gomas W., Jagsch R., Stühlinger G., Kasper S. Comparison of buprenorphine and methadone maintenance in opiate addicts. European Addiction Research 1998; 4: 3–7, Suppl.[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- EMCDDA European Conference on young people and drugs: conclusions, European Monitoring Centre for Drugs and Drug Addiction, released 3.11.2003. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Portugal
- Farquhar M. Definitions of quality of life: a taxonomy. Journal of Advanced Nursing 1995; 22: 502–508, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fischer G., Etzersdorfer P., Eder H., Jagsch R., Langer M., Weninger M. Buprenorphine maintenance in pregnant opiate addicts. European Addiction Research 1998; 4: 32–36, Suppl. 1[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fischer G., Gombas W., Eder H., Jagsch R., Peternell A., Stuhlinger G., Pezawas L., Aschauer H. N., Kasper S. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999a; 94: 1337–1347, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fischer G., Jagsch R., Eder H., Gombas W., Etzersdorfer P., Schmidl-Mohl K., Schatten C., Weninger M., Aschauer H. N. Comparison of methadone and slow-release oral morphine maintenance in pregnant addicts. Addiction 1999b; 94: 231–239, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fischer G., Eder H., Peternell A., Windhaber J. Lebensqualität gravider substanzabhängiger Frauen unter oraler Erhaltungstherapie mit synthetischen Opioiden. Nervenheilkunde 2000; 4: 2–9, [CSA]
- Franques P., Auriacome M., Grabot D., Ol J. Quality of life in methadone and buprenorphine maintenance treatment. Abstract book at the CPDD. Annual Meeting, Nashville, TN, 1997; 47
- Gandhi D. H., Jaffe J. H., McNary S., Kavanagh G. J., Hayes M., Currens M. Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users. Addiction 2003; 98: 453–462, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Garg N., Yates W. R., Jones R., Zhou M., Williams S. Effect of Gender, Treatment Site and Psychiatric Comorbidity on Quality of Life Outcome in Substance Dependence. American Journal of Addiction 1999; 8: 44–54, [CROSSREF], [CSA]
- Gerlach R., Schneider W. Methadon- und Codeinsubstitution-Erfahrungen, Forschungsergebnisse, Praxiskonsequenzen. Verlag für Wissenschaft und Bildung, Berlin 1994
- Gerra G., Borella F., Zaimovic A., Moi G., Bussandri M., Bubici C., Bertacca S. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug and Alcohol Dependence 2004a; 75: 37–45, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gerra G., Angioni L., Zaimovic A., Moi G., Bussandri M., Bertacca S., Santoro G., Gardini S., Caccavari R., Nicoli M. A. Substance use among high-school students: relationships with temperament, personality traits, and parental care perception. Substance Use & Misuse 2004b; 39: 345–367, [CROSSREF], [CSA]
- Giacomuzzi S. M., Riemer Y., Kemmler G., Ertl M., Richter R., Rössler H., Hinterhuber H. Substitutionsbehandlung und Lebensqualität: Methadon vs. Retardiertes Morphinsulfat—eine Vergleichsstudie. Suchtmedizin in Forschung Praxis 2001a; 3: 89–95, [CSA]
- Giacomuzzi S. M., Riemer Y., Kemmler G., Ertl M., Richter R., Rossler H., Hinterhuber H. Subjective wellbeing in heroin withdrawal. MMW Fortschritte der Medizin 2001b; 143: 53–55, [PUBMED], [INFOTRIEVE], [CSA]
- Giacomuzzi S. M., Riemer Y., Ertl M., Kemmler G., Rössler H., Hinterhuber H., Kurz M. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction 2003; 98: 693–702, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gossop M., Bradley B., Philips G. T. An investigation of withdrawal symptoms shown by opiate addicts during and subsequent to a 21-day in-patient methadone detoxification procedure. Addiction 1987; 12: 1–6, [CSA]
- Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addictive Behaviors 1990; 15: 487–490, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gowing L., Ali R., White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2004, CD002025[CSA]
- Grella C. E., Joshi V., Hser Y. I. Programme variation in treatment outcomes among women in residential drug treatment. Evaluation Reviews 2000; 24: 364–383, [CSA]
- Grunberger J., Linzmayer L., Fischer G., Pezawas L., Stohr H., Grunberger M. Central nervous system activation in opioid dependent patients, evaluation with Fourier analysis of pupillary oscillations. Wiener Klinische Wochenschrift 2000; 112(2)75–79, [PUBMED], [INFOTRIEVE], [CSA]
- Gunne L. M., Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug and Alcohol Dependence 1981; 7: 249–256, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Habrat B., Chmielewska K., Baran-Furga H., Keszycka B., Taracha E. Subjective Quality of Life in opiate-dependent patients before admission after six months and one-year participation in methadone program. Przeglad Lekarski 2002; 59: 351–354, [PUBMED], [INFOTRIEVE], [CSA]
- Huxley P., Oliver J., Priebe S., Kaiser W. Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Social Psychiatry Psychiatric Epidemiology 1997; 32: 76–83, [CSA]
- Huxley P., Evans S., Burns T., Fahy T., Green J. Quality of life outcome in a randomized controlled trial of case management. Social Psychiatry Psychiatric Epidemiology 2001; 36: 249–255, [CSA]
- Jasinski D. R., Pevnick J., Griffith J. Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry 1978; 35: 501–516, [PUBMED], [INFOTRIEVE], [CSA]
- Kolar A. F., Brown B. S., Weddington W. W., Ball J. C. A treatment crisis: cocaine use by clients in methadone maintenance programs. Journal Substance Abuse Treatment 1990; 7: 101–107, [CROSSREF], [CSA]
- Kosten T. R., Schottenfeld R., Ziedonis D., Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disease 1993; 181: 358–364, [PUBMED], [INFOTRIEVE], [CSA]
- Kraigher D., Ortner R., Eder H., Schindler S., Fischer G. Slow-release morphine hydrochloride for maintenance therapy of opioid dependence. Wiener Klinische Wochenschrift 2002; 114: 904–910, [PUBMED], [INFOTRIEVE], [CSA]
- Leavitt S., Shinderman M., Maxwell S., Eap C., Paris P. When “enough” is not enough: new perspectives on optimal methadone maintenance dose. Mount Sinai Journal of Medicine 2000; 67: 404–411, [PUBMED], [INFOTRIEVE], [CSA]
- Leiβe M., Kallert T. W. Social integration and the quality of life of schizophrenic patients in different types of complementary care. European Psychiatry 2000; 15: 450–460, [CROSSREF], [CSA]
- Ling W., Wesson D., Charuvastra C., Klett J. A Controlled Trial Comparing Buprenorphine and Methadone Maintenance in Opioid Dependence. Archives of General Psychiatry 1996; 53: 401–407, [PUBMED], [INFOTRIEVE], [CSA]
- Ling W., Charuvastra C., Collins J. F., Batki S., Brown L. S., Kintaudi P., Wesson D. R., McNicholas L., Tusel D. J. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93: 475–486, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mast M. E. Definition and measurement of quality of life in oncology nursing research: review and theoretical implications. Oncology Nursing Forum 1995; 22: 957–964, [PUBMED], [INFOTRIEVE], [CSA]
- McKellar J. Some statistical considerations in the development of new quality of life (QoL) scales in schizophrenia. European Psychiatry 1998; 13: 154–157, [CROSSREF], [CSA]
- Mercadante S., Casuccio A., Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. Journal of Clinical Oncology 1999; 17: 3307–3312, [PUBMED], [INFOTRIEVE], [CSA]
- Mitchell T. B., White J. M., Somogyi A. A., Bochner F. Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction 2004; 99: 940–945, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Newman R. G. Methadone treatment. New England Journal of Medicine 1987; 317: 447–450, [PUBMED], [INFOTRIEVE], [CSA]
- Noll H. H. Societal Indicators and Social Reporting: The International Experience. Denmark. 1998, QOL Research Centre
- ÖBIG. Bericht zur Drogensituation 2002. Österreichisches Bundesinstitut für Gesundheitswesen–Bundesministerium für soziale Sicherheit und Generationen. ÖBIG, Wien 2002
- Oliver J. The social care directive: development of a quality of life profile for use in community services for the mental ill. Social Work & Social Sciences Review 1991; 3: 5–45, [CSA]
- Oliver J., Huxley P., Bridges K., Mohamed H. Quality of Life and Mental Health Services. Routledge, London 1996
- Ortner R., Schindler S., Kraigher D., Fischer G. Kokainzusatzkonsum unter der Erhaltungstherapie mit Methadon. Wiener Klinische Wochenschrift 2001; 113: 934–938, [PUBMED], [INFOTRIEVE], [CSA]
- Pani P. P., Maremmani I., Piratsu R., Tagliamonte A., Gessa G. L. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug and Alcohol Dependence 2000; 60: 39–50, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Petry N. M., Bickel W. K., Badger G. J. A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible?. Addiction 2000; 95: 1069–1077, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Petry N. M., Bickel W. K., Badger G. J. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens. Addicition 2001; 96: 823–834, [CROSSREF], [CSA]
- Pezawas L., Fischer G., Podreka I., Schindler S., Brucke T., Jagsch R., Thurnher M., Kasper S. Opioid addiction changes cerebral blood flow symmetry. Neuropsychobiology 2002; 45: 67–73, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Powis B., Griffiths P., Gossop M., Strang J. The differences between male and female drug users: community samples of heroin and cocaine users compared. Substance Use & Misuse 1996; 31: 529–543, [CSA]
- Priebe S., Gruyters T., Heinze M., Hoffmann C., Jäkel A. Subjektive Evaluationskriterien in der psychiatrischen Versorgung—Erhebungsmethoden für Forschung und Praxis. Psychiatrische Praxis 1995; 22: 140–144, [PUBMED], [INFOTRIEVE], [CSA]
- Reno R. R., Aiken L. S. Life activities and life quality of heroin addicts in and out of methadone treatment. International Journal of Addiction 1993; 28: 211–232, [CSA]
- Ripamonti C., De Conno F., Groff L., Belzile M., Pereira J., Hanson J., Bruera E. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Annals of Oncology 1998a; 9: 79–83, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ripamonti C., Groff L., Brunelli C., Polastri D., Stavrakis A., De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?. Journal of Clinical Oncology 1998b; 16: 3216–3221, [PUBMED], [INFOTRIEVE], [CSA]
- Ritsner M., Modai I., Kurs R., Kostizky H., Ponizovsky A. A comparison between the Hebrew versions of the quality of life enjoyment and satisfaction questionnaire and the Lancashire quality of life profile in severely mentally ill patients. Quality of Life Newsletter 2001; 26: 12–13, [CSA]
- Expanding treatment options for heroin dependence in Victoria: buprenorphine, LAAM, naltrexone and slow-release oral morphine, A. Ritter, J. Kutin, N. Lintzeris, G. Bammer. New pharmacotherapies project—feasibility phase, Turning Point Alcohol and Drug Centre, Melbourne 1997
- Rohrmeister K., Bernert G., Langer M., Fischer G., Weninger M., Pollak A. Opiate addiction in gravidity—consequences for the newborn. Results of an interdisciplinary treatment concept. Zeitschrift fur Geburtshilfe und Neonatologie 2001; 205: 224–230, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ruggeri M., Bisoffi G., Fontecedro L., Warner R. Subjective and objective dimensions of quality of life in psychiatric patients: a factor analytical approach: The South Verona Outcome Project 4. British Journal of Psychiatry 2001; 178: 268–275, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Scherbaum N., Finkbeiner T., Leifert K., Gastpar M. The Efficacy of l-methadone and racemic methadone in substitution treatment of opiate addicts—a double-blind comparison. Pharmacopsychiatry 1996; 29: 212–215, [PUBMED], [INFOTRIEVE], [CSA]
- Schlatter J., Sitbon N., Saulnier J. L. Helping patients who misuse drugs. Drug Therapy Bulletin 1997; 35: 18–22, [CSA]
- Schneider C., Fischer G., Diamant K., Hauk R., Pezawas L., Lenzinger E., Kasper S. Pregnancy and drug dependence. Wiener Klinische Wochenschrift 1996; 108: 611–614, [PUBMED], [INFOTRIEVE], [CSA]
- Schoenbaum H., Selwyn P. A. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. American Journal of Public Health 1995; 85: 83–88, [PUBMED], [INFOTRIEVE], [CSA]
- Scholz H. Substitutionstherapie, was haben wir erreicht?. Facts & Figures 2004; 43: 14–15, [CSA]
- Schottenfeld R. S., Pakes J. R., Kosten T. Prognostic factors in buprenorphine versus methadone maintained patients. Journal of Nervous and Mental Disease 1998; 186(1)713–720, [CROSSREF], [CSA]
- Schwartz R. P., Brooner R. K., Montoya I. D., Currens M., Hayes M. A 12-Year Follow-up of a Methadone Medical Maintenance Program. American Journal of Addiction 1999; 8: 293–299, [CROSSREF], [CSA]
- Seidenberg A., Honegger Heroin U., andere Opioide-Medizinisches Manual für die ambulante opioidgestützte Behandlung, Bern Göttingen Toronto Seattle. 1998, Huber (partly translated on: Methadone, Heroin and other Opioids: A Medical Manual for Outpatient, Opioid-Supported Treatment http://www.druglibrary.org/schaffer/heroin/ase/index.htm
- Shaw M., Brabbins C., Ruben S. Misuse of benzodiazepines. British Medical Journal 1994; 308: 1709, [PUBMED], [INFOTRIEVE], [CSA]
- Sherman J. P. Managing heroin addiction with a long-acting morphine product (Kapanol). Medical Journal of Australia 1996; 165: 239, [PUBMED], [INFOTRIEVE], [CSA]
- Stöver H. Arbeit, Ausbildung und Qualifikation für Drogengebraucher in Substiutionsbehandlung. Deutsche Aids-Hilfe e.V, Berlin 1995
- Strain E. C., Stitzer M. L., Liebson I. A., Bigelow G. E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry 1994; 151: 1025–1030, [PUBMED], [INFOTRIEVE], [CSA]
- Torrens M., San L., Martinez A., Castillo C., Domingo-Salvany A., Alonso J. Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. Addiction 1997; 92: 707–716, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Torrens M., Domingo-Salvany A., Alonso J., Castillo C., San L. Methadone and quality of life. Lancet 1999; 353: 1101, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Uehlinger C., Deglon J. J., Livoti S., Petitjean S., Waldvogel D., Ladewig D. Comparison of buprenorphine and methadone in the treatment of opioid dependence. European Addiction Research 1998; 4: 13–18, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- van Nieuwenhuizen C., Schene A. H., Koeter M. W., Huxley P. The Lancashire Quality of Life Profile: modification and psychometric evaluation. Social Psychiatry and Psychiatric Epidemiology 2001; 36: 36–44, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ventegodt S., Merrick J. Psychoactive drugs and quality of life. Scientific World Journal 2003; 3: 694–706, [PUBMED], [INFOTRIEVE], [CSA]
- Vignau J., Brunelle E. Differences between General Practitioner- and Addiction Centre-Prescribed Substitution Therapy in France. Preliminary results. European Addiction Research 1998; 1: 24–28, [CROSSREF], [CSA]
- Walsh S. L., Preston K. L., Bigelow G. E., Stitzer M. L. Acute administration of buprenorphine in humans: partial agonist and blockade effects. Journal of Pharmacology and Experimental Therapeutics 1995; 274: 361–372, [PUBMED], [INFOTRIEVE], [CSA]
- West S. L., O'Neal K. K., Graham C. W. A meta-analysis comparing the effectiveness of buprenorphine and methadone. Journal of Substance Abuse 2000; 12: 405–414, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zaric G. S., Barnett P. G., Brandeau M. L. HIV transmission and the cost effectiveness of methadone maintenance. American Journal of Public Health 2000; 90: 1100–1111, [PUBMED], [INFOTRIEVE], [CSA]